Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01745198 · ClinicalTrials.gov registry record
Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements
A clinical trial of Mild Cognitive Impairment and Alzheimers Disease, sponsored by Pamlab.
- Completed
- Registry status
- 121
- Enrollment target
- 1
- Study location
NCT01745198: Completed study of Mild Cognitive Impairment and Alzheimers Disease, sponsored by Pamlab.
NCT01745198 is a study of Mild Cognitive Impairment and Alzheimers Disease that has completed, run by Pamlab. The registered enrollment target is 121 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01745198, a study of Mild Cognitive Impairment and Alzheimers Disease, has completed, sponsored by Pamlab.
- COMPLETED
- Registry status
- 121 participants
- Enrollment target
- 1
- Study location
Study Summary
In a retrospective analysis of data from 1100 patients, disease-delaying effects of Cerefolin®/CerefolinNAC® were examined in terms of cognition. The purpose of the current study is to expand the retrospective study dataset by prospectively collecting additional biomarker and imaging data.
Primary Outcome
Change in MPI over time will be calculated using multiple retrospective time points.
Conditions Studied
Study Locations (1)
California
- Hoag Memorial Hospital - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-06 |
What the finished NCT01745198 record still lists
NCT01745198 is an observational study that tracks outcomes without assigning an intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (90% lower).
The record links to 3 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 0 interventions.
NCT01745198 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01745198 about?
NCT01745198 is a clinical study titled "Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements". In a retrospective analysis of data from 1100 patients, disease-delaying effects of Cerefolin®/CerefolinNAC® were examined in terms of cognition. The purpose of the current study is to expand the retrospective study dataset by prospectively collecting additional biomarker and imaging data.
What is the current status of trial NCT01745198?
This trial is currently completed. The enrollment target is 121 participants. The study started on 2012-12. Estimated completion is 2014-06.
What conditions does trial NCT01745198 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, Alzheimers Disease, Alzheimer's Disease Related Disorders.
Who is sponsoring clinical trial NCT01745198?
This trial is sponsored by Pamlab, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01745198 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01745198's enrollment target sits among peer trials
121 77th of 205 higher than 128 of 205 other Mild Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Wayfinding Intervention and Long-Term Memory
RECRUITING · NA
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
MCI Speech in Noise
RECRUITING
-
Dual Task Perturbation Training for OAwMCI
RECRUITING · NA
-
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
RECRUITING
-
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia